Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs.

Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising ...

Novo Nordisk (NVO) closed the most recent trading day at $65.29, moving 2.61% from the previous trading session.

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including SAP SE, Novo Nordisk A/S and ...

In the latest trading session, Novo Nordisk (NVO) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a ...

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

NVO Return on Equity Image Source: Zacks Investment Research Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.